Comments on Bu et al. "P16(INK₄a) overexpression and survival in osteosarcoma patients: a meta analysis".
Recently, we read the article "P16(INK4a) overexpression and survival in osteosarcoma patients: a meta analysis" by Jie Bu and his colleagues, published in the recent issue of International Journal Of Experimental Pathology. This research performed a meta-analysis to uncover the role of P16(INK4a) expression in overall survival rate in patients with osteosarcoma. The investigators concluded as follows: (i) the pateints with overexpression of P16(INK4a) had a longer overall survival rate than that with loss expression of P16(INK4a); (ii) P16(INK4a) was an effective biomarker of prognosis in patients with osteosarcoma.The findings are valubale and encouraging. However, some flaws and imperfections rooted in this work.
Department of Orthopeadic Surgery, Second Xiangya Hospital of Central South University China.
Ming-Ming
MM
Yan
Department of Orthopeadic Surgery, Second Xiangya Hospital of Central South University China.
Jiang-Dong
JD
Ni
D014408:Biomarkers, Tumor / Q000032:analysis*; D001859:Bone Neoplasms / Q000737:chemistry*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000032:analysis*; D006801:Humans; D012516:Osteosarcoma / Q000737:chemistry*
D014408:Biomarkers, Tumor; D019941:Cyclin-Dependent Kinase Inhibitor p16
Osteosarcoma; P16INK4a; meta-analysis